Skip to main content
padlock icon - secure page this page is secure

Open Access On-demand drug release and re-absorption from pirarubicin loaded Fe3O4@ZnO core–shell nanoparticles for targeting infusion chemotherapy for urethral carcinoma

Download Article:
(PDF 9,279.9 kb)
Although standard treatment recommendations for urethral carcinoma are lacking due to its rare incidence, urethral infusion chemotherapy can be a good choice for urethral carcinoma therapy which minimizes damage to patients compared to radical cystourethrectomy and radiation therapy. In this work, pirarubicin loaded Fe3O4@ZnO core–shell nanoparticles have been successfully synthesized. They can magnetically position in a tubular structure at will and realized on-demand pirarubicin release and re-absorption under UV radiation and darkness. As a result, they can strongly inhibit the human urethral squamous carcinoma cells during infusion chemotherapy and give nearly no damage to normal cells after infusion chemotherapy. Overall, such nanoparticles are highly possible to be a new approach for urethral carcinoma infusion chemotherapy, with satisfactory efficacy and slight side effects.

25 References.

No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: August 1, 2019

More about this publication?
  • Materials Express is a peer-reviewed multidisciplinary journal reporting emerging researches on materials science, engineering, technology and biology. Cutting-edge researches on the synthesis, characterization, properties, and applications of a very wide range of materials are covered for broad readership; from physical sciences to life sciences. In particular, the journal aims to report advanced materials with interesting electronic, magnetic, optical, mechanical and catalytic properties for industrial applications.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more